(VIANEWS) – The Market ended the session with PCI BIOTECH HOLD (PCIB.OL) rising 33.49% to kr2.28 on Monday while Oslo Børs Benchmark Index_GI jumped 0.37% to kr1,268.48.
PCI BIOTECH HOLD’s last close was kr1.71, 71.2% under its 52-week high of kr5.93.
About PCI BIOTECH HOLD
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-0.79.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -47.54%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 84.4%, now sitting on 2.79M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
PCI BIOTECH HOLD’s EBITDA is -4.54.
More news about PCI BIOTECH HOLD (PCIB.OL).
